Ikena Oncology, Inc. reported its financial results for the first quarter ended March 31, 2025, showing a net loss of $8.62 million. This marks a significant improvement compared to a net loss of $16.15 million reported in the same quarter a year ago. The company's efforts in cost management contributed to this narrowed loss.
The basic loss per share from continuing operations for the first quarter of 2025 was $0.18. This is an improvement from the $0.33 basic loss per share from continuing operations reported in the first quarter of 2024.
Similarly, the diluted loss per share from continuing operations for the quarter was $0.18, also an improvement from $0.33 a year ago. These figures reflect the company's financial trajectory as it prepared for its strategic merger and pivot.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.